Malignant ascites: Systematic review and guideline for treatment

被引:218
作者
Becker, G
Galandi, D
Blum, HE
机构
[1] Univ Hosp Freiburg, Dept Internal Med 2, D-79106 Freiburg, Germany
[2] HELIOS Hosp, Dept Internal Med, D-79822 Titisse Neustadt, Germany
[3] Univ Hosp Freiburg, German Cochrane Ctr, Dept Med Stat, D-79104 Freiburg, Germany
关键词
ascites; neoplasms; paracentesis; diuretics; peritoneovenous shunt;
D O I
10.1016/j.ejca.2005.11.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A guideline on the management of symptomatic malignant ascites by abdominal paracentesis, diuretics and peritoneovenous shunting, based on a systematic review of the literature is presented. Thirty-two relevant studies were identified. None were randomized control trials, one was a non-randomized open controlled trial, five were cohort studies or prospective uncontrolled trials, 26 studies were non-analytic studies like case series. Although paracentesis, diuretics and shunting are commonly used procedures, the evidence is weak. Available data show good, although temporary effect of paracentesis on symptom relief. Fluid withdrawal speed and concurrent intravenous hydration is not sufficiently studied. Peritoneovenous shunts can control ascites in patients with malignant ascites, but have to be balanced by the potential risks of this procedure. The available data about diuretics in treatment of malignant ascites are controversial. The use of diuretics therefore should be considered in all patients, but has to be evaluated individually (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:589 / 597
页数:9
相关论文
共 89 条
[1]   Malignant ascites: Past, present, and future [J].
Adam, RA ;
Adam, YG .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2004, 198 (06) :999-1011
[2]  
[Anonymous], 1998, Palliative Care Formulary
[3]   ON THE TREATMENT AND PROGNOSIS OF MALIGNANT ASCITES - IS THE SURVIVAL-TIME DETERMINED WHEN THE ABDOMINAL PARACENTESIS IS NEEDED [J].
APPELQVIST, P ;
SILVO, J ;
SALMELA, L ;
KOSTIAINEN, S .
JOURNAL OF SURGICAL ONCOLOGY, 1982, 20 (04) :238-242
[4]  
ARIEL IM, 1966, CANCER, V19, P1096, DOI 10.1002/1097-0142(196608)19:8<1096::AID-CNCR2820190808>3.0.CO
[5]  
2-N
[6]  
Beattie GJ, 1998, CLIN CANCER RES, V4, P1899
[7]  
Bieligk SC, 2001, CANCER-AM CANCER SOC, V91, P1247, DOI 10.1002/1097-0142(20010401)91:7<1247::AID-CNCR1125>3.0.CO
[8]  
2-W
[9]   Octreotide as an agent for the relief of malignant ascites in palliative care patients [J].
Cairns, W ;
Malone, R .
PALLIATIVE MEDICINE, 1999, 13 (05) :429-430
[10]  
Chen BM, 1997, INT J CANCER, V73, P392, DOI 10.1002/(SICI)1097-0215(19971104)73:3<392::AID-IJC14>3.0.CO